null
100% Quality Guarantee
PhD-Level Technical Support
Key Features

Ascrinvacumab ELISA Kit (GXEL00185)

SKU GXEL00185
Product Type ELISA Kit
Assay Type Quantitative
Detection Method Colorimetric
Sensitivity 0.156 μg/ml
Range 0.31-5 μg/mL
Size 96T
Synonyms PF-03446962, , 1463459-96-2
€880
Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

Ascrinvacumab ELISA Kit

Assay Genie's Ascrinvacumab ELISA Kit (SKU: GXEL00185) provides researchers with a reliable quantitative ELISA for the quantitative measurement of Ascrinvacumab in Plasma, Serum. Offering a measurement range of 0.31-5 μg/mL and a sensitivity of 0.156 μg/ml, the kit is optimised for precision and ease of use in the research laboratory.

Ascrinvacumab, also known as PF-03446962 or anti-hALK1 antibody, is a human immunoglobulin G (IgG) 2 monoclonal antibody which can be used as therapeutic antibody drug for the treatment of many tumors. It has been found that the clinical trials of ascrinvacumab has been developed in cancers including advanced solid tumors, urothelial cell carcinoma, hepatocellular carcinoma, and mesothelioma. Ascrinvacumab can binding to ACVRL1 by recognizing the extracellular domain of ACVRL1. ACVRL1, also called activin receptor-like kinase 1 (ALK1), is a transforming growth factor β (TGF-β) type I receptor. Ascrinvacumab is a fully human monoclonal antibody generated by immunizing the IgG 2 transgenic XenoMouse. In a human/mouse chimera tumor model, ascrinvacumab decreased human vessel density and improved antitumor efficacy when combined with bevacizumab (anti-VEGF). It suggests that ascrinvacumab therapy may be complementary to anti-VEGF in cancer intervention. As early as 2012, researchers had investigated the effects of ascrinvacumab on endothelial cell function. And the results showed that ascrinvacumab do interferes with the endothelial cell sprouting induced by Bone Morphogenetic Protein 9 (BMP9). A phase 2 trial study of ascrinvacumab in pre-treated patients with urothelial cancer had been reported in 2014. In addition, its treatment results of advanced solid tumors, hepatocellular carcinoma, and advanced malignant pleural mesothelioma also had been reported in 2016. In addition to advanced malignant pleural mesothelioma, ascrinvacumab shows the value of continuing treatment evaluation in the other two diseases.

Complete with standards, buffers and detection reagents, the Ascrinvacumab ELISA Kit streamlines assay set-up so you can focus on results. Choose the Ascrinvacumab ELISA Kit from Assay Genie for quality you can trust.

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose